

Supplementary material 1. Clinical characteristics of the 68 pediatric cases of salivary gland secretory carcinoma identified in the literature.

N	Author-date	Country	Sex	Age	Localization	Symptoms	Evolution (months)	Size (cm)	Treat.	Rec.	Met.	Follow-up (months)	Additional
CASES AND SERIES REPORT													
1	Rastatter (2012) ¹	USA	F	14	Parotid (R)	Painless	4	4	S, ND	No	Regional	NED (12)	Facial nerve preservat.
2	Keisling (2014) ²	USA	F	05	Buccal mucosa (R)	Painful	4	1.9 (MRI)	S	NI	No	NI	Painful (after trauma)
3	Woo (2014) ³	USA	M	11	Parotid (L)	NI	12	1.5	S	NI	NI	NI	Secondary tumor from ATRT; Facial nerve dissected
4	Hwang (2014) ⁴	Taiwan	M	13	Parotid (L)	Painless	36	3	S	No	No	NED (8)	-
5	Quattlebaum (2015) ⁵	USA	F	15	Parotid (L)	NI	NI	3	S	NI	No	NI	Facial nerve dissected
6	Inaba (2015) ⁶	Japan	F	15	Parotid (L)	NI	12	2.8 (CT)	S	No	No	NED (40)	-
7	Joshi (2015) ^{7,8}	Indian	M	15	Parotid (R)	Painless	18	20	S	Yes	No	NI	Facial nerve dissected
8	Ngouaji (2017) ⁸	USA	M	14	Parotid (L)	Painless	NI	3	S, ND	No	No	NED (14)	Facial nerve dissected
9	Chen et al. (2018) ⁹	Taiwan	F	12	Parotid (R)	NI	2	2	S	No	No	NI	Facial nerve preservat.
10	Shigeta (2018) ¹⁰	Japan	M	07	Parotid (L)	NI	12	5	S	No	No	NED (20)	Probable rec. tumor
11	Gonzalez (2018) ¹¹	USA	M	18	Parotid (L)	NI	12	1.5 (MRI)	S, ND	NI	No	NED	-
12	Shukla (2018) ¹²	Indian	M	17	Parotid (L)	Painless	18	3	S	No	No	NED (7)	Facial nerve preservat.
13	Black (2020) ¹³	USA	M	18	Parotid (R)	Painful	12	2.5	S	No	No	NED (9)	Painful (after FNAC)
14	Helmy (2020) ¹⁴	USA	F	11	Parotid (R)	Painless	2	2	S	No	No	NED (6)	Facial nerve dissected
15	Jha (2021) ¹⁵	Indian	F	17	Parotid (R)	NI	NI	NI	S	NI	NI	NI	-
16	Simon (2022) ¹⁶	USA	M	09	Parotid (R)	Painless	0.46	1.4	S	No	No	NED (30)	-
17			M	11	Hard Palate (L)	Painless	60	1	S	No	No	NED (30)	-
18			M	15	Upper lip (R)	Painless	6	0.9	S	No	No	NED (30)	-
19			M	18	Parotid (R)	Painless	NI	2.7	S	NI	NI	NI	-
20	Kelly (2022) ¹⁷	USA	M	13	Parotid (L)	Painless	60	2.1 (MRI)	S	No	No	NED (24)	-
21			M	16	Parotid (R)	NI	NI	2.5 (MRI)	S, ND	No	Regional	NED (24)	History of ALL
22	Mehta (2022) ¹⁸	Indian	F	16	Submandibular (L)	Painless	5	2	S	No	No	NED (6)	-
23	Meng (2023) ¹⁹	China	M	04	Parotid (R)	Painless	NI	2.5	S	No	No	NED (24)	-
24	Ash (2023) ²⁰	UK	M	13	Parotid (L)	Painless	6	0.9	S	NI	Regional	NI	DM Type 1 history Facial nerve preservat.
25	Moreddu (2023) ²¹	France	M	08	Parotid (L)	NI	4	NI	S	No	No	NED (24)	Brief report
26			F	12	Parotid (L)	Painless	2	NI	S	No	No	NED (24)	-
27	Cardoni (2023) ²²	Italy	F	12	Maxillary sinus (R)	NI	NI	6.2 (CT)	CH, TRKi, S	No	No	NED (16)	-
28	Serrano-Meneses (2024) ²³	Mexico	M	11	Parotid (L)	NI	24	4	S	No	No	NED	-
29	Kapatia (2024) ²⁴	Indian	M	16	Submandibular (R)	Painless	24	2.7 (CT)	S	NI	NI	NED (4)	-
30	Asuquo (2024) ²⁵	USA	M	17	Uper Lip	Painful	24	2.5 (MRI)	S, RT, CH	No	Regional	NED (6)	Vesicles
31	Tolentino (2024) ²⁶	Brazil	F	14	Hard palate	Painless	24	1	S, RT	No	No	NED (12)	-
32	Fadhil (2025) ²⁷	Australia	F	16	Parotid (L)	Painful	12	3.4 (MRI)	S, ND, RT	No	Regional	NED (8)	Tender to palpation

33	Samal (2025) ²⁸	Indian	F	17	Parotid (R)	NI	6	6	S	No	No	NED (24)	Facial nerve dissected
34	Our case (2025)	Brazil	M	16	Parotid (R)	Painless	24	5	S	No	No	NED (24)	-
LETTER TO THE EDITOR													
35	Griffith (2011) ²⁹	USA	M	15	Upper lip	NI	NI	1	S	NI	NI	NI	-
OTHER TYPES OF STUDIES: CLINICOPATHOLOGICAL AND RETROSPECTIVE OBSERVATIONAL STUDIES													
36	Jung (2014) ³⁰	Korea	F	17	Parotid	NI	NI	1	NI	Yes	NI	NI	-
37			M	17	Parotid	NI	NI	1.5	NI	No	NI	NED	-
38	Ito (2015) ^{31,32}	Japan	F	10	Submandibular	NI	NI	3.8	S	NI	NI	NI	
39	Urano (2015) ³²	Japan	F	14	Parotid	NI	24	2.8	S	No	No	NED (24)	-
40	Shah (2015) ³³	USA	F	16	Parotid (R)	NI	NI	NI	NI	NI	NI	NI	-
41	Majewska (2015) ³⁴	Poland	M	17	Parotid	NI	NI	4.3	S	No	No	NED (120)	-
42	Skálová (2016) ³⁵	Czech Republic	M	15	Submandibular	NI	NI	1.8	S, RT	No	Yes	NED (48)	-
43			M	17	Parotid	NI	NI	4.0	S	No	No	NED (144)	-
44	Oza (2016) ³⁶	Indian	F	09	Parotid (R)	Painless	3	1	S	No	No	NED (6)	Brief report
45			F	16	Parotid (R)	Painless	8	2	S	No	No	NED (9)	
46	Evrard (2017) ³⁷	France	F	11	Parotid	NI	NI	NI	S	NI	NI	NI	-
47	Xu (2017) ³⁸	USA	M	8	Parotid	NI	NI	NI	NI	No	No	NED (21)	-
48			M	9	Parotid	NI	NI	NI	NI	No	No	NED (111)	-
49			F	15	Parotid	NI	NI	NI	NI	No	No	NED (155)	-
50			F	18	Lip	NI	NI	1	NI	Yes	No	NED (92)	-
51	Forner (2018) ³⁹	Canadian	M	06	Parotid (R)	NI	4	NI	S, ND, RT	NI	NI	NI	-
52	Kashiwagi (2018) ⁴⁰	Japan	F	14	Parotid	NI	NI	1.5	S	NI	No	NI	-
53	Kuwabara (2018) ⁴¹	Japan	F	15	Parotid	NI	NI	NI	S	NI	No	NED	-
54			F	14	Parotid	NI	NI	NI	S	NI	No	NI	-
55	Hernandez-Prera (2019) ⁴²	USA	F	17	Parotid	NI	NI	NI	S	No	No	NI	-
56	Yoshino (2020) ⁴³	Japan	F	10	Submandibular (R)	NI	NI	NI	S, RT	No	No	NED (72)	LLA history
57	Lee (2020) ⁴⁴	S. Korea	M	15	Parotid (L)	NI	8	3	S, RT	No	No	NED (35)	-
58	Salgado (2021) ⁴⁵	USA	M	07	Parotid	Painless	NI	1.5	S	No	No	NED (52)	-
59			M	09	Parotid	Painless	NI	1.3	S	No	No	NED (30)	-
60			F	14	Submandibular	Painless	NI	2.1	S	No	No	NED (20)	-
61			F	14	Parotid	Painless	NI	1.2	S	No	No	NED (12)	-
62	Csanyi-Bastien (2021) ⁴⁶	France	M	18	Parotid	NI	NI	NI	S	NI	NI	NI	-
63			M	13	Parotid	NI	NI	NI	S	NI	NI	NI	-
64			F	14	Submandibular	NI	NI	NI	S	NI	NI	NI	-
65	Hamamoto (2021) ⁴⁷	Japan	M	15	Parotid	NI	NI	6	S	No	No	NED (60)	High-grade
66	Budhiraja (2021) ⁴⁸	Indian	M	16	Parotid (R)	Palsy (facial)	24	2	S	No	No	NED (38)	Facial nerve involv.
67			M	15	Buccal mucosa	NI	48	3	S, ND, RT	Yes	No	NED (29)	-

68	Durzyńska (2023) ⁴⁹	Poland	F	4	Parotid	S+RT+CH	Yes	Regional	NI (377)	-
-----------	--------------------------------	--------	---	---	---------	---------	-----	----------	----------	---

Supplementary material 1. Pathological characteristics of the 68 pediatric cases of salivary gland secretory carcinoma identified in the literature.

N	FNAC	Pattern	PNI	LVI	NEC	Positive IHC (+)	Negative IHC (-)	Ki-67/MYB1	Mol. status
CASES AND SERIES REPORT									
1	NI	Papillary, microcystic	-	-	NI	S-100, PAS		NI	ETV6-NTRK3
2	NI	Microcystic	-	-	NI	Mammaglobin, S-100, Vimentin, AE1/AE3, EMA, CK7, Mucicarmine	DOG-1, CK14	10-15%	ETV6-NTRK3
3	SGT	Microcystic, tubular and solid	-	NI	NI	S-100, Vimentin, EGFR, mucicarmine.	DOG-1, P63, PAS-D (zymogen granules absent)	NI	ETV6-rearrangement
4	NI	Microcystic, tubular, solid and papillary	-	-	NI	S-100, CK19, Vimentin, PAS-D/PAS (mucin)	DOG-1, P63, CK5/6, CEA, α1-antichymotrypsin.	NI	ETV6-NTRK3
5	NI	Microcystic, papillary	NI	NI	NI	S-100, CK19	NI	NI	ETV6-rearrangement
6	AciCC	Tubular, microcystic	-	-	NI	Mammaglobin, S-100, PAS (eosinophilic material)	P63GCDP-15, ER, PR, HER2.	22%	ETV6-NTRK3
7	NI	Nests, lobules	-	-	+	S-100, CK7, CK19, Vimentin, EMA, GCDP15, CD10, PAS (cystic)	DOG-1, CK20, PR, SMA, CD34, Carcinoembryonic antigen,	15-20%	NI
8	SC	Microcystic, tubular, solid	-	-	NI	Mammaglobin, S-100, PAS-D (lumen)	DOG-1, GATA-3, BRST-2, Mucicarmine	NI	ETV6-NTRK3
9	NI	Microcystic	-	-	NI	S-100, CK7, S100, GATA3, PAS, mucicarmine	DOG-1, P63, Actin, calponin	NI	ETV6-NTRK3
10	Lymphatic malformation	Microcystic	NI	NI	NI	Mammaglobin, S-100, GCDP-15, Vimentin, CAM 5.2		NI	ETV6-NTRK3
11	Low grade adenocarcinoma (MEC)	Microcystic, macrocystic, papillary, cribriform, solid, follicular	-	-	-	Mammaglobin, S-100, Broad spectrum cytokeratin, SOX-10, MUC-1, MUC-4, p63 (focal) and GCDP-15	Myoepithelial markers	NI	ETV6-NTRK3
12	MEC	Solid, cystic, tubular, papillary	-	NI	-	Mammaglobin, S-100, Pan-CK, EMA PAS, mucicarmine, alcian blue	DOG-1, Calponin, GCDP1, DOG1, ER, PR, Her2neu, SMA	NI	NT
13	Benign	Cribriform, papillary	-	NI	-	Mammaglobin, S-100, CK7, GATA-3, p63 (f)	Androgen receptor, CK5/6, Calponin	NI	ETV6-RET, EGFR-SEPT14
14	Descriptive	Microcystic and tubular	NI	NI	NI	Mammaglobin, S-100	DOG-1		ETV6-rearrangement
15	Salivary duct adenocarcinoma	Cystic, papillary and solid	NI	NI	+	Mammaglobin, S-100, GCDP, EMA	DOG-1, P63, CEA, SMA, CK20.	NI	NI
16	SC	Tubular	-	-	NI	Mammaglobin, S-100		NI	ETV6-NTRK3
17	Low-grade lesion	Microtubular	-	-	NI	Mammaglobin, S-100, PAS (secretions)	DOG-1, P63, ER	NI	NT
18	NI	Microtubular	-	-	NI	S-100	P63	NI	NT
19	NI	Cystic and lobular	-	-	NI	Mammaglobin, S-100, Mucin	DOG-1, P63, P40, SMA	NI	NT

20	Myoepithelial neoplasm	Microcystic	-	-	NI	S-100, CK7		NI	ETV6-NTRK3
21	NI	Microcystic	NI	NI	NI	Mammaglobin, S-100	NI	NI	ETV6-NTRK3
22	EMC, PA	NI	NI	NI	NI	Mammaglobin, GCDFP-15, mucicarcine and PAS (secretions)		NI	NI
23	NI	Solid, tubular, and papillary	-	-	-	Mammaglobin, S-100, CK7, pan-TRK, P63 (f)	DOG-1, CK5/6, C-KIT	15%	ETV6-NTRK3
24	PA, MA	Solid, microcystic, macrocystic, papillary and tubular	NI	NI	-	S-100, CK7, PAS-D (secretions)	DOG-1, P63	15%	ETV6-rearrangement
25	NI	Solid and microcystic	NI	NI	NI	Mammaglobin, S-100, SOX10	P40	NI	ETV6-NTRK3
26	Epithelial tumor	Microcystic	NI	NI	NI	Mammaglobin, S-100, SOX10		NI	ETV6-NTRK3
27	NI	Papillary and tubular/follicular	+	-	+	S-100, AE1/AE3, Vimentin, CK7, EMA, SOX10, GATA3, MUC4, Pan-TRK, DOG-1 (f)	P63, GCDFP-15, SMA	60%	ETV6-NTRK3
28	NI	Tubular and cystic	NI	NI	NI	S-100, AE1/AE3, CK7, GATA3, PAS (eosinophilic material)	P63, Actin	20%	NI
29	Myo neoplasia, AcCC, SC	Solid and cystic	-	NI	-	Mammaglobin, S-100, CK7		NI	NI
30	NI	NI	-	NI	NI			NI	NI
31	NI	Packed lobules and microcystic	NI	-	-			NI	NI
32	Oncocytic neoplasia	Cords and papillae	+	+	NI	Mammaglobin, S-100, SOX10, GATA3, CK7		NI	ETV6-NTRK
33	NI	Cystic	-	-	NI	Mammaglobin, S-100, GCDFP – 15, EMA	DOG-1, P63, ER, PR	15%	NI
34	NI	Solid, cribriform, and micropapillary	-	-	-	Mammaglobin, S-100, AE1/AE3, Pan-TRK, GATA-3	P63, Calponin, AR	NI	NI
LETTER TO THE EDITOR									
35	NOS neoplasia	NI	NI	NI	NI	S-100, PAS-D	NI	NI	ETV6-rearrangement
OTHER TYPES OF STUDIES: CLINICOPATHOLOGICAL AND RETROSPECTIVE OBSERVATIONAL STUDIES									
36	MEC	NI	NI	NI	NI	NI	NI	NI	ETV6-NTRK3
37	PA	NI	NI	NI	NI	NI	NI	NI	ETV6-NTRK3
38	NI	NI	-	-	-	Mammaglobin, S-100	NI	NI	ETV6-rearrangement
39	NI	Microcystic and solid	NI	NI	NI	S-100, Vimentin, CK19, LMWCK	PAS-D (zymogen granules)	NI	ETV6-NTRK3
40	NI	Solid and microcystic	NI	-	-	Mammaglobin, S-100, AE1/AE3, CAM5.2, CK7, CK19	DOG-1, SMA	NI	ETV6-rearrangement negative
41	AcicCC	Macrocystic	NI	NI	NI	Mammaglobin, S-100, CK7, CK8, STAT5a, Vimentin	DOG-1, S-100	NI	ETV6 rearrangement
42	NI	NI	+	-	NI	Mammaglobin, S-100, CK7	DOG-1, S-100	NI	ETV6-NTRK3
43	NI	NI	-	-	NI	Mammaglobin, S-100, CK7	DOG-1, S-100	NI	ETV6-NTRK3

44	MEC	Solid, tubular, and microcystic	-	-	-	Mammaglobin, S-100, CK7, PAS and mucicarmine (secretions)	DOG-1, S-100	NI	NT
45	AcCC, SC	Solid, tubular, and microcystic	-	-	-	Mammaglobin, S-100, CK7, PAS and mucicarmine (secretions)	DOG-1, S-100	NI	NT
46	Myoepithelial neoplasia	NI	NI	NI	NI	NI	NI	NI	NI
47	NI	Papilocystic and microcystic	+	NI	NI	NI	NI	NI	NI
48	NI	Microcystic/ductal and solid	-	NI	NI	NI	NI	NI	NI
49	NI	Papilocystic and microcystic	-	NI	NI	NI	NI	NI	NI
50	NI	Papilocystic and microcystic	+	NI	NI	NI	NI	NI	NI
51	No malignant	Microcystic and solid	NI	NI	NI	Mammaglobin, S-100, CK7	NI	NI	NI
52	NI	Papillary-cystic and follicular	NI	NI	NI	NI	NI	NI	NI
53	NI	Solid and cystic	NI	NI	NI	Mammaglobin, S-100	DOG-1, Alpha-amylase	NI	ETV6-NTRK3
54	NI	Cyst and solid	NI	NI	NI	Mammaglobin, S-100	DOG-1, Alpha-amylase	NI	ETV6-NTRK3
55	NI	Macrocytic	-	-	-	Mammaglobin, S-100, PAS-D, mucicarmine, P63 (f)	DOG-1	NI	ETV6 rearrang. (-)
56	NI	NI	NI	NI	NI	NI	NI	NI	ETV6-NTRK3
57	MEC	Microcystic/macrocystic, tubular, solid and papillary	-	-	-	Mammaglobin, S-100	DOG-1	NI	NI
58	SG epithelioid neoplasm	Solid and microcystic	-	-	NI	Mammaglobin, S-100, CK7, GATA3	P63, CK5/6	20-30%	ETV6-NTRK3
59	NI	Solid and microcystic	-	-	NI	Mammaglobin, S-100, CK7, GATA3	P63, CK5/6	20-30%	ETV6-NTRK3
60	NI	Solid and microcystic	-	-	NI	Mammaglobin, S-100, CK7, GATA3	P63, CK5/6	20-30%	ETV6-NTRK3
61	NI	Solid and microcystic	-	-	NI	Mammaglobin, S-100, CK7, GATA3	P63, CK5/6	20-30%	ETV6-NTRK3
62	NI	Microcystic, papillary, solid or tubular	NI	NI	NI	Mammaglobin, S-100, Pan-TRK	NI	NI	ETV6-NTRK3
63	NI	Microcystic, papillary, solid or tubular	NI	NI	NI	Mammaglobin, S-100, Pan-TRK	NI	NI	ETV6-NTRK3
64	NI	Microcystic, papillary, solid or tubular	NI	NI	NI	Mammaglobin, S-100, Pan-TRK	NI	NI	ETV6-RET
65	NI	Solid, trabecular and papillary	NI	NI	NI	Mammaglobin, S-100, p-STAT5	DOG-1, P63	23%	ETV6-NTRK3
66	PA	Solid sheets and microcystic	-	NI	NI	S-100, CK7, Vimentin, GCDFP-15	NI	10	NT
67	Benign	Solid and microcystic	-	NI	NI	S-100, CK7, Vimentin, GCDFP-15, PAS-D, PAS	NI		NT
68	PA	Macrocytic, solid	NI	NI	NI	S-100, PanTRK, GATA3, GCDFP-15	Mammaglobin, DOG-1, P63, CK7		ETV6-NTRK3

FNAC: Fine-needle aspiration cytology, SGT: salivar gland tumor, AcCC: acinic cell carcinoma, EPC: epithelial-myoepithelial carcinoma, PA: pleomorphic adenoma, MEC: mucoepidermoid carcinoma, NI: no informed, NT: no tested

1. Rastatter JC, Jatana KR, Jennings LJ, Melin-Aldana H. Mammary Analogue Secretory Carcinoma of the Parotid Gland in a Pediatric Patient. *Otolaryngology–Head and Neck Surgery* [Internet]. 2012 Mar 26;146(3):514–515. Available from: <http://journals.sagepub.com/doi/10.1177/0194599811419044>
2. Keisling M, Bianchi M, Pascasio JM. Mammary analog secretory carcinoma of salivary gland in a 5 year old: Case report. *Int J Pediatr Otorhinolaryngol Extra* [Internet]. Elsevier Ltd; 2014;9(4):163–165. Available from: <http://dx.doi.org/10.1016/j.pedex.2014.09.003>
3. Woo J, Seethala RR, Joseph Sirintrapun S. Mammary Analogue Secretory Carcinoma of the Parotid Gland as a Secondary Malignancy in a Childhood Survivor of Atypical Teratoid Rhabdoid Tumor. *Head Neck Pathol*. 2014;8(2):194–197. PMID: 23921806
4. Hwang MJ, Wu PR, Chen CM, Chen CY, Chen CJ. A rare malignancy of the parotid gland in a 13-year-old Taiwanese boy: Case report of a mammary analogue secretory carcinoma of the salivary gland with molecular study. *Med Mol Morphol*. 2014;47(1):57–61. PMID: 23955668
5. Quattlebaum SC, Roby B, Dishop MK, Said MS, Chan K. A pediatric case of mammary analogue secretory carcinoma within the parotid. *American Journal of Otolaryngology - Head and Neck Medicine and Surgery* [Internet]. Elsevier Inc.; 2015;36(6):741–743. Available from: <http://dx.doi.org/10.1016/j.amjoto.2015.05.005> PMID: 26545463
6. Inaba T, Fukumura Y, Saito T, Yokoyama J, Ohba S, Arakawa A, Yao T. Cytological Features of Mammary Analogue Secretory Carcinoma of the Parotid Gland in a 15-Year-Old Girl: A Case Report with Review of the Literature. *Case Rep Pathol*. Hindawi Publishing Corporation; 2015;2015:1–6.
7. Joshi P, Mridha A, Singh S, Kinra P, Ray R, Thakar A. Large lipid-rich mammary analogue secretory carcinoma of parotid gland: An unusual case. *Indian J Pathol Microbiol* [Internet]. 2015;58(3):351. Available from: <http://www.ijpmonline.org/text.asp?2015/58/3/351/162897>
8. Ngouajio AL, Drejet SM, Phillips DR, Summerlin DJ, Dahl JP. A systematic review including an additional pediatric case report: Pediatric cases of mammary analogue secretory carcinoma. *Int J Pediatr Otorhinolaryngol* [Internet]. Elsevier Ireland Ltd; 2017;100:187–193. Available from: <http://dx.doi.org/10.1016/j.ijporl.2017.07.004> PMID: 28802370
9. Chen YC, Hsu HT, Lin YH, Chen LC, Lin YF. Mammary analog secretory carcinoma of the parotid gland: A case of a 12-year-old Taiwanese girl. *International Journal of Pediatric Otorhinolaryngology Case Reports* [Internet]. Elsevier; 2018;20(252):14–17. Available from: <https://doi.org/10.1016/j.pedeo.2018.04.001>
10. Shigeta R, Orgun D, Mizuno H, Hayashi A. Mammary analogue secretory carcinoma arising in the parotid gland of child. *Plast Reconstr Surg Glob Open*. 2018;6(12):1–3.
11. Gonzalez MF, Akhtar I, Manucha V. Additional diagnostic features of mammary analogue secretory carcinoma on cytology. *Cytopathology*. 2018;29(1):100–103. PMID: 28929545
12. Shukla S, Kashyap A, Sharma S, Kamal L. Mammary Analogue Secretory Carcinoma- A Salivary Gland Neoplasm: Case Report of an Exceptionally Rare Tumour. *JOURNAL OF CLINICAL AND DIAGNOSTIC RESEARCH* [Internet]. 2018; Available from: http://jcdr.net/article_fulltext.asp?issn=0973-709x&year=2018&volume=12&issue=4&page=ED01&issn=0973-709x&id=11351

13. Black M, Liu CZ, Onozato M, Iafrate AJ, Darvishian F, Jour G, Cotzia P. Concurrent Identification of Novel EGFR–SEPT14 Fusion and ETV6–RET Fusion in Secretory Carcinoma of the Salivary Gland. *Head Neck Pathol* [Internet]. Springer US; 2020;14(3):817–821. Available from: <https://doi.org/10.1007/s12105-019-01074-6> PMID: 31502214
14. Helmy D, Chang J, Bishop JW, Vong A, Raslan O, Ozturk A. MR imaging findings of a rare pediatric parotid tumor: Mammary analogue secretory carcinoma. *Radiol Case Rep* [Internet]. Elsevier Inc.; 2020;15(9):1460–1463. Available from: <https://doi.org/10.1016/j.radcr.2020.05.035>
15. Jha S, Samal S, Ayyanar P, Mishra P, Purkait S, Sable MN, Pradhan P, Adhya AK. Cytomorphological features of Mammary Analog secretory carcinoma of parotid gland. *Indian J Pathol Microbiol*. 2021 Oct;64(4):783–787.
16. Simon CT, McHugh JB, Rabah R, Heider A. Secretory Carcinoma in Children and Young Adults: A Case Series. *Pediatric and Developmental Pathology* [Internet]. 2022 Mar 4;25(2):155–161. Available from: <http://journals.sagepub.com/doi/10.1177/10935266211046996>
17. Kelly GA, Venkatramani R, Quintanilla NM, Chelius DC, Roy A, Mahajan P. Secretory Carcinoma of the Salivary Gland: A Rarity in Children. *J Pediatr Hematol Oncol* [Internet]. 2022 May;44(4):167–172. Available from: <https://journals.lww.com/10.1097/MPH.0000000000002304>
18. Mehta R, Chakravarty S, Nagarkar NM, Gupta AK, Banjare A. Mammary Analogue Secretory Carcinoma of Submandibular gland. *Iran J Otorhinolaryngol*. Mashhad University of Medical Sciences; 2022 May 1;34(3):191–197.
19. Meng Z, Si W, Xiuli Z, Liu Y. A Parotid Gland Mammary Analogue Secretory Carcinoma in a 4-Year-Old Boy: Case Report and Literature Review. *Fetal Pediatr Pathol* [Internet]. 2023 Mar 4;42(2):342–350. Available from: <https://www.tandfonline.com/doi/full/10.1080/15513815.2022.2116621>
20. Ash J, Mallick S, Vogiatzis P, Philpott J. Secretory carcinoma in the parotid gland of a pediatric patient. A challenging diagnosis. *Journal of Oral and Maxillofacial Pathology*. 2023 Apr;27(2):420–423.
21. Moreddu E, André N, Appay R. Mammary-analog secretory carcinoma in children: Surgery or TRK inhibitors first? *Pediatr Blood Cancer* [Internet]. 2023 Sep 20;70(9). Available from: <https://onlinelibrary.wiley.com/doi/10.1002/pbc.30504>
22. Cardoni A, De Vito R, Milano GM, De Pasquale MD, Alaggio R. A Pediatric Case of High-Grade Secretory Carcinoma of the Maxillary Sinus With *ETV6::NTRK3* Gene Fusion, Therapeutic Implications, and Review of the Literature. *Pediatric and Developmental Pathology*. 2023 Jan 30;26(1):59–64.
23. Serrano-Meneses GJ, Brenes Guzmán S, Serrano-Meneses MA, Delgado-Porras A. Insights Into Pediatric Secretory Carcinoma of the Salivary Gland: A Case Report. *Cureus*. 2024 May 15;
24. Kapatia G, Kaur M, Jain D, Rajasekaran S, Rajan N, Soni A, Sekar A. A tale of recurrent secretory carcinoma of submandibular gland in an adolescent male: A rare presentation of a rare tumor. *Diagn Cytopathol*. 2024 Nov 24;52(11).
25. Asuquo J, Blavo C, Bhatta R. Secretory Carcinoma of the Philtrum of the Upper Lip: A Case Study. *Cureus*. 2024 Sep 6;

26. de Souza Tolentino E, Jacomacci WP, Camarini C, Sedassari BT, de Miranda FV, Cardoso CL. Salivary gland secretory carcinoma: A case presentation in minor salivary gland with review. *J Stomatol Oral Maxillofac Surg*. 2025 Jun;126(3):102096.
27. Fadhil M, Nury Z, Pearson SJ. Parotid secretory carcinoma with high-risk features in a paediatric patient: case report and review of the literature. *AME Med J*. 2025 Jun;10:19–19.
28. Samal DK, Parida PK, Adhya AK, Pradhan P. Mammary Analogue Secretory Carcinoma of the Parotid at Younger Age: An Unusual Entity. *Indian Journal of Otolaryngology and Head & Neck Surgery*. 2025 Mar 1;77(3):1651–1653.
29. Griffith C, Seethala R, Chiosea SI. Mammary analogue secretory carcinoma: A new twist to the diagnostic dilemma of zymogen granule poor acinic cell carcinoma. *Virchows Archiv*. 2011;459(1):117–118. PMID: 21638010
30. Jung MJ, Kim SY, Nam SY, Roh JL, Choi SH, Lee JH, Baek JH, Cho KJ. Aspiration cytology of mammary analogue secretory carcinoma of the salivary gland. *Diagn Cytopathol* [Internet]. 2015 Apr;43(4):287–293. Available from: <http://doi.wiley.com/10.1002/dc.23208>
31. Ito Y, Ishibashi K, Masaki A, Fujii K, Fujiyoshi Y, Hattori H, Kawakita D, Matsumoto M, Miyabe S, Shimozaoto K, Nagao T, Inagaki H. Mammary analogue secretory carcinoma of salivary glands: A clinicopathologic and molecular study including 2 cases harboring ETV6-X fusion. *American Journal of Surgical Pathology*. 2015;39(5):602–610. PMID: 25651470
32. Urano M, Nagao T, Miyabe S, Ishibashi K, Higuchi K, Kuroda M. Characterization of mammary analogue secretory carcinoma of the salivary gland: Discrimination from its mimics by the presence of the ETV6-NTRK3 translocation and novel surrogate markers. *Hum Pathol* [Internet]. Elsevier Inc.; 2015;46(1):94–103. Available from: <http://dx.doi.org/10.1016/j.humpath.2014.09.012> PMID: 25456394
33. Shah AA, Wenig BM, LeGallo RD, Mills SE, Stelow EB. Morphology in Conjunction with Immunohistochemistry is Sufficient for the Diagnosis of Mammary Analogue Secretory Carcinoma. *Head Neck Pathol*. 2015;9(1):85–95. PMID: 25078757
34. Majewska H, Skálová A, Stodulski D, Klimková A, Steiner P, Stankiewicz C, Biernat W. Mammary analogue secretory carcinoma of salivary glands: a new entity associated with ETV6 gene rearrangement. *Virchows Archiv*. 2015;466(3):245–254. PMID: 25503077
35. Skálová A, Vanecek T, Simpson RHW, Laco J, Majewska H, Baneckova M, Steiner P, Michal M. Mammary Analogue Secretory Carcinoma of Salivary Glands: Molecular Analysis of 25 ETV6 Gene Rearranged Tumors With Lack of Detection of Classical ETV6-NTRK3 Fusion Transcript by Standard RT-PCR: Report of 4 Cases Harboring ETV6-X Gene Fusion. *Am J Surg Pathol* [Internet]. 2016 Jan;40(1):3–13. Available from: <https://doi.org/10.1097/pas.0000000000000537> PMID: 26492182
36. Oza N, Sanghvi K, Shet T, Patil A, Menon S, Ramadwar M, Kane S. Mammary analogue secretory carcinoma of parotid: Is preoperative cytological diagnosis possible? *Diagn Cytopathol* [Internet]. 2016 Jun;44(6):519–525. Available from: <https://onlinelibrary.wiley.com/doi/10.1002/dc.23459>
37. Evrard SM, Meilleroux J, Daniel G, Basset C, Lacoste-Collin L, Vergez S, Uro-Coste E, Courtade-Saidi M. Use of fluorescent in-situ hybridisation in salivary gland cytology: A powerful diagnostic tool. *Cytopathology*. 2017 Aug 15;28(4):312–320.
38. Xu B, Aneja A, Ghossein R, Katabi N. Salivary gland epithelial neoplasms in pediatric population: a single-institute experience with a focus on the histologic spectrum and clinical outcome. *Hum Pathol* [Internet]. Elsevier Inc.; 2017;67:37–44. Available from: <http://dx.doi.org/10.1016/j.humpath.2017.07.007> PMID: 28739497

39. Forner D, Bullock M, Manders D, Wallace T, Chin CJ, Johnson LB, Rigby MH, Trites JR, Taylor MS, Hart RD. Secretory carcinoma: The eastern Canadian experience and literature review. *Journal of Otolaryngology - Head and Neck Surgery*. *Journal of Otolaryngology - Head & Neck Surgery*; 2018;47(1). PMID: 30446016
40. Kashiwagi N, Nakatsuka S, Murakami T, Enoki E, Yamamoto K, Nakanishi K, Chikugo T, Kurisu Y, Kimura M, Hyodo T, Tsukabe A, Kakigi T, Tomita Y, Ishii K, Narumi Y, Yagyu Y, Tomiyama N. Mr imaging features of mammary analogue secretory carcinoma and acinic cell carcinoma of the salivary gland: A preliminary report. *Dentomaxillofacial Radiology*. 2018;47(5). PMID: 29493279
41. Kuwabara H, Yamamoto K, Terada T, Kawata R, Nagao T, Hirose Y. Hemorrhage of MRI and Immunohistochemical Panels Distinguish Secretory Carcinoma From Acinic Cell Carcinoma. *Laryngoscope Investig Otolaryngol*. 2018;3(4):268–274.
42. Hernandez-Prera JC, Holmes BJ, Valentino A, Harshan M, Bacchi CE, Petersson F, Liu KK, Najfeld V, Wenig BM. Macrocystic (Mammary Analogue) Secretory Carcinoma. *American Journal of Surgical Pathology*. 2019 Nov;43(11):1483–1492.
43. Yoshino H, Nishiyama Y, Kamma H, Chiba T, Fujiwara M, Karaho T, Kogashiwa Y, Morio T, Yan K, Bessho F, Takagi M. Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood. *Int J Hematol* [Internet]. Springer Singapore; 2020;112(2):217–222. Available from: <https://doi.org/10.1007/s12185-020-02885-y> PMID: 32367453
44. Lee DH, Kim JH, Yoon TM, Lee JK, Lim SC. Outcomes of treatment of mammary analogue secretory carcinoma of the parotid gland. *British Journal of Oral and Maxillofacial Surgery* [Internet]. British Association of Oral and Maxillofacial Surgeons; 2020;58(2):158–162. Available from: <https://doi.org/10.1016/j.bjoms.2019.11.003> PMID: 31859109
45. Salgado CM, Alaggio R, Reyes-Múgica M, Zin A, de Vito R. Clinicopathologic and Molecular Characterization of Four Cases of Pediatric Salivary Secretory Carcinoma (SSC), One with ETV6-RET Fusion. *Head Neck Pathol* [Internet]. 2021 Sep 18;15(3):796–802. Available from: <https://link.springer.com/10.1007/s12105-021-01288-7>
46. Csanyi-Bastien M, Lanic MD, Beaussire L, Ferric S, François A, Meseure D, Jardin F, Wassef M, Ruminy P, Laé M. Pan-TRK Immunohistochemistry Is Highly Correlated With NTRK3 Gene Rearrangements in Salivary Gland Tumors. *American Journal of Surgical Pathology*. 2021 Nov;45(11):1487–1498.
47. Hamamoto Y, Harada H, Kohara M, Honma K, Nakatsuka S ichi, Morii E. Usefulness of immunohistochemistry to distinguish between secretory carcinoma and acinic cell carcinoma in the salivary gland. *Med Mol Morphol* [Internet]. Springer Singapore; 2020; Available from: <https://doi.org/10.1007/s00795-020-00256-4> PMID: 32488412
48. Budhiraja S, Kumar R, Khanna G, Sagar P, Arava S, Barwad A, Mridha A. Secretory carcinoma of salivary gland origin: A recently established masquerader. *Indian J Cancer*. 2021;58(2):278.
49. Durzyńska M, Dominiak K, Sosnowska I, Michalek IM. Secretory carcinoma of major and minor salivary glands with ETV6-NTRK3 gene fusion: overcoming misdiagnosis in the era of tumour-agnostic therapy with TRK inhibitors. *Współczesna Onkologia*. 2023;27(2):101–108.